Global Forum
-
Gene therapy in hemophilia a hot topic at the WFH Global Forum 2019
Gene therapy in hemophilia featured heavily at the World Federation of Hemophilia Global Forum held in Montréal November 13 to 14, 2019. Glenn Pierce, MD,...
-
11th WFH Global Forum to feature talk on blood and plasma safety
The 11th WFH Global Forum on Research and Treatment Products for Bleeding Disorders is taking place at the Westin Hotel in Montreal on November 13...
-
Now available: proceedings of the 10th WFH Global Forum
The Proceedings of the 10th WFH Global Forum on Research and Treatment Products for Bleeding Disorders are now available online. The 10th WFH Global Forum—held...
-
Unmet needs and unfinished business in gene therapy
Three experts on gene therapy in hemophilia presented during the final session on day one of the 10th World Federation of Hemophilia Global Forum held...
-
Inhibitors: solving the problem
Three experts on inhibitors in hemophilia opened the first session of the 10th World Federation of Hemophilia (WFH) Global Forum held in Montreal on November...
-
Kenneth Mann to give talk at 10th WFH Global Forum
The World Federation of Hemophilia (WFH) is very pleased to announce that we will be welcoming Kenneth Mann, MD, PhD, at this year’s WFH Global...
-
Global Forum to cover research, product safety, supply, and access
The tenth World Federation of Hemophilia (WFH) Global Forum on Research and Treatment Products for Bleeding Disorders will take place in Montreal, Canada, on November...
-
Ninth WFH Global Forum on Research and Treatment Products for Bleeding Disorders
Access to safe and effective treatment products continues to improve each year due to the tireless advocacy from the global bleeding disorders community. This strategic priority...
-
Clinical Research Grant supports new clinical investigations
Lize van Vulpen knows that without the assistance of the World Federation of Hemophilia (WFH) Clinical Research Grant she might never have been able to...
-
Global Forum speakers highlight need for inhibitor surveillance
Inhibitors—antibodies to infused factor VIII or factor IX produced by the immune system, making treatment ineffective—are the foremost treatment complication faced by people with hemophilia...
